Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt Ratio: 2018-2022

Historic Debt Ratio for Theravance Biopharma (TBPH) over the last 3 years, with Jun 2022 value amounting to 1.10.

  • Theravance Biopharma's Debt Ratio rose 23.38% to 1.10 in Q2 2022 from the same period last year, while for Jun 2022 it was 1.10, marking a year-over-year increase of 23.38%. This contributed to the annual value of 1.04 for FY2021, which is 23.90% up from last year.
  • According to the latest figures from Q2 2022, Theravance Biopharma's Debt Ratio is 1.10, which was down 0.76% from 1.11 recorded in Q1 2022.
  • Theravance Biopharma's Debt Ratio's 5-year high stood at 1.11 during Q1 2022, with a 5-year trough of 0.41 in Q4 2018.
  • Its 3-year average for Debt Ratio is 0.90, with a median of 0.93 in 2021.
  • Data for Theravance Biopharma's Debt Ratio shows a peak YoY skyrocketed of 67.00% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Debt Ratio stood at 0.41 in 2018, then skyrocketed by 36.81% to 0.56 in 2019, then soared by 49.18% to 0.84 in 2020, then climbed by 23.90% to 1.04 in 2021, then increased by 23.38% to 1.10 in 2022.
  • Its Debt Ratio was 1.10 in Q2 2022, compared to 1.11 in Q1 2022 and 1.04 in Q4 2021.